The overall goal of the Clinical Trials Office (CTO) is to provide central management, research support and oversight functions for coordinating, facilitating and conducting human research and reporting results in conjunction with members of the Yale Cancer Center (YCC). The CTO provides a broad range of management and quality control functions, including trial activation and monitoring, centralized protocol document directory, a centralized database of protocol-specific data, data and safety reporting, and assistance with complex regulatory issues. The CTO further provides high quality services involving assistance with patient enrollment, screening, obtaining informed consent and safety reporting. Specific objectives are to: 1. Facilitate timely institutional approval and implementation of clinical trials and translational research; 2. Ensure the research team is adequately trained, qualified and prepared to support each trial; 3. Maintain a centralized web-based repository of all protocol specific documents and consents; 4. Provide clinical assistance and facilitate the conduct of clinical trials (institutional and multi-center) via centralized clinical trial operations, including but not limited to enrollment and verification of patient eligibility, scheduling of appropriate tests, treatments, and assessment; 5. Verify trial data and provide electronic data capture and data management; 6. Insure that all reports, including reports of serious adverse events and unanticipated problems, are , submitted in accordance with institutional and federal regulatory guidelines to appropriate regulatory bodies, including local and central IRBs and sponsors;and 7. Insure protocol compliance with all institutional policies and agreements, state and federal regulations, data accuracy and data integrity through a system of monitoring and quality assurance that is consistent with the YCC Data and Safety Monitoring Plan (DSMP). 8. Carry out the research priorities and functions as determined by the YCC leadership and PRMS committees. The activity and usage of the CTO parallels the growth of the center. As the number of YCC investigators has increased with the number of oncology faculty, the usage of the CTO has increased. For example, in the year (2005) preceding the previous grant submission, 143 patients had been enrolled onto therapeutic trials. In the five years preceding this grant submission 1531 patients have been enrolled onto therapeutic trials, with 471 accrued in the most recent fiscal year (FY12). A number of efficiencies have allowed CTO to maintain quality services and increase in the number of staff. With the rapid expansion of staff to meet the demands, the CTO provides high quality services to the YCC investigators, allowing protocol compliance and conduct consistent with excellence in clinical research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016359-34
Application #
8558317
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-07-01
Project End
2018-07-31
Budget Start
2013-09-09
Budget End
2014-07-31
Support Year
34
Fiscal Year
2013
Total Cost
$237,367
Indirect Cost
$94,804
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Jagannath, Sundar; Laubach, Jacob; Wong, Ellice et al. (2018) Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. Br J Haematol 182:495-503
Liu, Xiaoni; Zhang, Shang-Min; McGeary, Meaghan K et al. (2018) KDM5B Promotes Drug Resistance by Regulating Melanoma Propagating Cell Subpopulations. Mol Cancer Ther :
Chae, Wook-Jin; Bothwell, Alfred L M (2018) Therapeutic Potential of Gene-Modified Regulatory T Cells: From Bench to Bedside. Front Immunol 9:303
Kim, Hanseul; Keum, NaNa; Giovannucci, Edward L et al. (2018) Garlic intake and gastric cancer risk: Results from two large prospective US cohort studies. Int J Cancer 143:1047-1053
Sarma, Elizabeth A; Kawachi, Ichiro; Poole, Elizabeth M et al. (2018) Social integration and survival after diagnosis of colorectal cancer. Cancer 124:833-840
Hartman, Douglas J; Ahmad, Fahad; Ferris, Robert L et al. (2018) Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma. Oral Oncol 86:278-287
Chen, Ling; Azuma, Takeshi; Yu, Weiwei et al. (2018) B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction. Proc Natl Acad Sci U S A 115:3126-3131
Zhang, Jinhua; Song, Kun; Wang, Jun et al. (2018) S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity. Oncoimmunology 7:e1296996
Kelada, Olivia J; Decker, Roy H; Nath, Sameer K et al. (2018) High Single Doses of Radiation May Induce Elevated Levels of Hypoxia in Early-Stage Non-Small Cell Lung Cancer Tumors. Int J Radiat Oncol Biol Phys 102:174-183
Powles, Ryan L; Redmond, David; Sotiriou, Christos et al. (2018) Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 4:e181564

Showing the most recent 10 out of 675 publications